MARKET

VERU

VERU

VERU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.060
-0.030
-0.97%
After Hours: 3.000 -0.06 -1.96% 18:00 08/07 EDT
OPEN
3.070
PREV CLOSE
3.090
HIGH
3.080
LOW
2.980
VOLUME
441.37K
TURNOVER
--
52 WEEK HIGH
4.740
52 WEEK LOW
1.670
MARKET CAP
208.10M
P/E (TTM)
-19.8187
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VERU stock price target is 8.50 with a high estimate of 13.00 and a low estimate of 6.00.

EPS

VERU News

More
VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19
\--VERU-111 significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome in COVID-19 in a toxic shock model-- --VERU-111’s ability to disrupt microtubules has potential for dual drug action against COVID-19: treat SARS-CoV-2 virus infect
GlobeNewswire · 4d ago
Veru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13th
MIAMI, July 30, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its
GlobeNewswire · 07/30 12:30
Veru Receives Positive Input From FDA On Phase 3 Pivital Trial To Evaluate VERU-111 In Metastatic Castration Resistant Prostate Cancer
Benzinga · 07/23 12:31
Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer
\--Pivotal Phase 3 Clinical Trial Expected to Initiate First Quarter Calendar Year 2021--MIAMI, July 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the man
GlobeNewswire · 07/23 12:30
Do Options Traders Know Something About Veru (VERU) Stock We Don't?
Zacks · 07/06 14:45
Veru Inc. Added to the Russell 2000 and 3000 Indices
GlobeNewswire · 06/29 13:30
Veru Inc. Added To Russell 2000 And 3000 Indices
Benzinga · 06/29 12:37
Veru (VERU) Soars: Stock Adds 6.9% in Session
Zacks · 06/25 13:44

Industry

Pharmaceuticals
+0.19%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About VERU

Veru Inc. is an oncology and urology biopharmaceutical company developing medicines for prostate cancer treatment and prostate cancer supportive care, as well as urology specialty pharmaceuticals. Its oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase II clinical trial for the treatment of hot flashes in men, and VERU-100, which is a gonadotropin-releasing hormone (GnRH) antagonist. Its urology specialty pharmaceutical drug candidate is Tadalafil and Finasteride Combination (TADFIN), which is a tadalafil and finasteride combination oral capsule for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal Condom for prevention of pregnancy and sexually transmitted infections, and PREBOOST wipes for the prevention of premature ejaculation.
More

Webull offers kinds of Veru Inc stock information, including NASDAQ:VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VERU stock methods without spending real money on the virtual paper trading platform.